Table 1.
Clinical, biological, and pathological features of the MIBC patients included in the prognostic model (MibcMLP).
| TCGA (N = 326) | RHWU (N = 144) | |
|---|---|---|
| Age (years) | 68 (57, 79) | 66 (26, 87) |
| Sex | ||
| female | 87 (26.69%) | 21 (14.58%) |
| male | 239 (73.31%) | 123 (85.42%) |
| pT stage | ||
| pT2 | 99 (30.37%) | 58 (40.28%) |
| pT3 | 158 (48.47%) | 67 (46.53%) |
| pT4 | 42 (12.88%) | 19 (13.19%) |
| pTx | 27 (8.28%) | 0 (0%) |
| pN stage | ||
| pN0 | 179 (54.91%) | 71 (49.31%) |
| pN1 | 38 (11.66%) | 37 (25.69%) |
| pN2 | 67 (20.55%) | 20 (13.89%) |
| pN3 | 6 (1.84%) | 16 (11.11%) |
| pNx | 36 (11.04%) | 0 (0%) |
| pM stage | ||
| pM0 | 138 (42.33%) | 140 (97.22%) |
| pM1 | 8 (2.45%) | 4 (2.78%) |
| pMx | 180 (55.22%) | 0 (0%) |
| pTNM stage | ||
| Stage II | 106 (32.52%) | 41 (28.47%) |
| Stage III | 104 (31.90%) | 81 (56.25%) |
| Stage IV | 115 (35.28%) | 22 (15.28%) |
| Missing | 1 (0.31%) | 0 (0%) |
| Lymphovascular invasion | ||
| No | 100 (30.67%) | 91 (63.19%) |
| Yes | 121 (37.12%) | 53 (36.81%) |
| Missing | 105 (32.21%) | 0 (0%) |
| Survival status | ||
| Alive | 180 (55.21%) | 79 (54.86%) |
| Dead | 146 (44.79%) | 65 (45.14%) |
| OS time (months) | 18.1 (0, 165.6) | 16.0 (1.9, 66.0) |
MIBC, Muscle-invasive bladder cancer.